Omitting aspirin in PCI patients: Myth or reality?
AbstractIn the current era of percutaneous coronary intervention (PCI), with the use of contemporary drug-eluting stents, refined techniques, and adjunctive pharmacotherapy, the role of aspirin peri-PCI remains undisputable. Beyond the initial period, dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 receptor inhibitor for 6 months in stable coronary artery disease and 12 months in acute coronary syndromes is the standard of care. However, concerns regarding bleeding adverse events caused by aspirin have led to shortened DAPT duration or even omission of aspirin. Aspirin free-strategies have been increasin...
Source: Cardiovascular Drugs and Therapy - December 6, 2019 Category: Cardiology Source Type: research

Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management
AbstractPulmonary arterial hypertension is a rare disease, with drug-induced causes even more uncommon, accounting for only 10% of cases in large registry series. Predisposing factors for drug-induced PAH have not been completely defined. This review summarizes drugs with definite, possible, or likely association to pulmonary hypertension and possible mechanisms involved in the occurrence of pulmonary hypertension. Controversies on mechanisms and on their role in pathophysiology were also shown. The possible synergism between drug abuse and HIV was discussed and the possible interactions of antiretroviral therapy in HIV su...
Source: Cardiovascular Drugs and Therapy - December 6, 2019 Category: Cardiology Source Type: research

The Effect of Ranolazine on Glycemic Control: a Narrative Review to Define the Target Population
AbstractRanolazine is an anti-anginal medication that reduces the sodium-dependent calcium overload via the inhibition of the late sodium current. After its approval for the treatment of chronic angina in 2006 in the USA, ranolazine has been reported to have several pleiotropic effects on various cardiac conditions, such as atrial fibrillation, ventricular arrhythmias, diastolic and microvascular dysfunction, and pulmonary arterial hypertension. Recently, several studies reported some promising results on the potential benefits of ranolazine on glycemic control. Though the mechanism of the antihyperglycemic effect is still...
Source: Cardiovascular Drugs and Therapy - December 4, 2019 Category: Cardiology Source Type: research

From the Choice of a Regimen to the Choice of an Intensity: Changing Perspective in the Antithrombotic Therapy of Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - December 2, 2019 Category: Cardiology Source Type: research

Five-Year Outcomes of Biodegradable Polymer Drug-Eluting Stents Versus Second-Generation Durable Polymer Drug-Eluting Stents: a Meta-Analysis of Randomized Controlled Trials
ConclusionAt 5  years of follow-up, the safety and efficacy of BP-DES are clinically comparable to those of second-generation DP-DES. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - November 26, 2019 Category: Cardiology Source Type: research

State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications
AbstractStatins are currently the primary treatment for hyperlipidemia, particularly for the treatment of high levels of low-density lipoprotein cholesterol (LDL-C), as many studies have proven benefit in a variety of populations. The benefits of statin treatment for high cholesterol have been proven in many trials. Forefront among different adverse events is statin-induced myopathy, which still eludes complete understanding, and may range anywhere from muscle soreness or fatigue to potentially extremely rare occurrence of rhabdomyolysis.As most adverse events are rare and not life-threatening, in high-risk patients, a hig...
Source: Cardiovascular Drugs and Therapy - November 26, 2019 Category: Cardiology Source Type: research

Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis
ConclusionsThe meta-analysis shows that the DOACs had greater effectiveness and safety compared to warfarin in real-world practice for stroke prevention, among Asian patients with NVAF. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - November 19, 2019 Category: Cardiology Source Type: research

Trends for and Clinical Factors Associated with Choice of Oral P2Y 12 Inhibitors for Patients on Chronic Dialysis
ABSTRACTBackgroundTrends and clinical factors associated with prescribing choices for oral P2Y12 inhibitors (P2Y12-I) remain unknown for patients on chronic dialysis, i.e., with end-stage renal disease (ESRD).MethodsFrom 2011 –2014 U.S. Renal Data System registry, we identified 36,542 ESRD patients who received new prescriptions for P2Y12-I (median age 64.0 years and 54% males). Of the cohort, 93% were receiving hemodialysis and 7% on peritoneal dialysis. We analyzed trends and investigated clinical factors associated with specific P2Y12-I prescribed.ResultsClopidogrel was prescribed for 95%, prasugrel for 3%, and ti...
Source: Cardiovascular Drugs and Therapy - November 15, 2019 Category: Cardiology Source Type: research

Association of Regulatory Genetic Variants for Protein Kinase C α with Mortality and Drug Efficacy in Patients with Heart Failure
ConclusionsA recently discovered cardiac-specific regulatory variant forPRKCA (rs9909004) was independently associated with a decreased risk for all-cause mortality in patients with HF. The variant did not interact with mortality benefit associated with cornerstone HF pharmacotherapies. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - November 14, 2019 Category: Cardiology Source Type: research

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues —Liraglutide and Semaglutide
ConclusionInfarct-limiting and functional neuroprotective effects of liraglutide are dose-dependent. Neuroprotection by semaglutide is at least as strong as by liraglutide and is mediated by GLP-1Rs. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - November 13, 2019 Category: Cardiology Source Type: research

Impact of Ca 2+ -Sensitive Potassium Channels in Levosimendan-Induced Postconditioning
AbstractPurposeSmall and big conductance Ca2+-sensitive potassium (KCa) channels are involved in cardioprotective measures aiming at reducing myocardial reperfusion injury. For levosimendan, infarct size –reducing effects were shown. Whether activation of these channels is involved in levosimendan-induced postconditioning is unknown. We hypothesized that levosimendan exerts a concentration-dependent cardioprotective effect and that both types of Ca2+-sensitive potassium channels are involved.MethodsIn a prospective blinded experimental laboratory investigation, hearts of male Wistar rats were randomized and placed on...
Source: Cardiovascular Drugs and Therapy - November 8, 2019 Category: Cardiology Source Type: research

Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives
ConclusionsIt is reasonable to measure Lp(a) levels to reclassify ASCVD risk and manage individuals with elevated Lp(a) to further reduce the residual risk of ASCVD, especially with IONIS-APO(a)-LRX. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - October 26, 2019 Category: Cardiology Source Type: research

The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart
ConclusionsOur findings suggest that MitoGamide, a novel mitochondria-targeted approach, offers cardioprotection in experimental diabetes and therefore may offer therapeutic potential for the treatment of cardiomyopathy in patients with diabetes. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - October 25, 2019 Category: Cardiology Source Type: research

Bleeding Risk Scores and Scales of Frailty for the Prediction of Haemorrhagic Events in Older Adults with Acute Coronary Syndrome: Insights from the FRASER study
ConclusionsBoth the bleeding risk scores and the scales of frailty predicted BARC 3-5 haemorrhages. However, integrating the scales of frailty with the bleeding risk scores did not improve their discriminative ability.Clinical trial registrationwww.clinicaltrials.gov: NCT02386124 (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - September 23, 2019 Category: Cardiology Source Type: research

Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation
AbstractPurposeTo study whether polypharmacy or drug –drug interactions have differential effect on safety and efficacy in patients treated with direct oral anticoagulants (DOACs) versus warfarin.MethodsWe performed a systematic review and meta-analysis of studies that randomized patients with atrial fibrillation to DOACs or warfarin stratified by the number of concomitant drugs. Outcomes included stroke or systemic embolism (SE), all-cause mortality, major bleeding, and intracranial hemorrhage. Risk ratios (RR) were calculated and Mantel-Haenszel random effects were applied.ResultsTwo high-quality studies were eligi...
Source: Cardiovascular Drugs and Therapy - September 13, 2019 Category: Cardiology Source Type: research

Cardiovascular Effects of Urocortin-2: Pathophysiological Mechanisms and Therapeutic Potential
AbstractUrocortin-2 (Ucn-2) is a peptide of the corticotrophin releasing factor-related family with several effects within the cardiovascular system. A variety of molecular mechanisms has been proposed to underlie some of these effects, although others remain mostly hypothetical. Growing interest in the cardiovascular properties of this peptide promoted several pre-clinical studies in the settings of heart failure and ischemia, as well as some experiments in the fields of systemic and pulmonary arterial hypertension. Most of these studies report promising results, with Ucn-2 showing therapeutic potential in these settings,...
Source: Cardiovascular Drugs and Therapy - September 11, 2019 Category: Cardiology Source Type: research

Chewed or Crushed Administration of Adenosine Diphosphate Receptor Inhibitors in Acute Coronary Syndromes: a Systematic Review and Meta-analysis of Randomized Controlled Trials
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - September 4, 2019 Category: Cardiology Source Type: research

Angiotensin II Type 1 Receptor Antagonist Azilsartan Restores Vascular Reactivity Through a Perivascular Adipose Tissue-Independent Mechanism in Rats with Metabolic Syndrome
ConclusionsOur results provide evidence supporting the use of azilsartan for the long-term protection against vascular dysfunctions in MetS. Azilsartan did not improve the dysfunction of PVAT-mediated modulation of vascular tone during MetS. The protective effect of azilsartan is mediated by restoring the endothelium- and vascular smooth muscle-mediated mechanisms. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - August 16, 2019 Category: Cardiology Source Type: research

Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2 ™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population
ConclusionsDYDA 2 is the first randomized, double-blind, placebo-controlled trial to explore the effect of a dipeptidyl peptidase-4 inhibitor on LVSF in T2DM patients in primary prevention regardless of glycemic control. The main characteristics of the enrolled population are reported.Trial registrationClinicalTrial.gov Identifier: NCT02851745. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - August 15, 2019 Category: Cardiology Source Type: research

Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon
AbstractSuccessful reperfusion of an infarct-related coronary artery by primary percutaneous intervention or fibrinolysis during acute ST-elevation myocardial infarction (STEMI) does not always restore myocardial tissue perfusion, a phenomenon termed “no-reflow.” Herein we discuss the pathophysiology of this highly prevalent phenomenon and highlight the most salient aspects of its clinical diagnosis and management as well as the limitations of presently used methods. There is a great need for understanding the dynamic nature of no-reflow, as its occurrence is associated with poor cardiovascular outcomes. The no...
Source: Cardiovascular Drugs and Therapy - August 15, 2019 Category: Cardiology Source Type: research

Response Letter to Letter by Venu Jonnalagadda
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - August 8, 2019 Category: Cardiology Source Type: research

The Associations of Diuretics and Laxatives Use with Cardiovascular Mortality. An Individual Patient-Data Meta-analysis of Two Large Cohort Studies
ConclusionsThese consistent results from two large cohort studies imply that more research is needed on the safety of diuretics in routine care. Although not statistically significant in this study, a drug-drug interaction of non-potassium-sparing diuretics and laxatives appears plausible. Physicians and pharmacists are advised to clarify additional laxative use in users of non-potassium-sparing diuretics and inform about the risk of concurrent use. Moreover, closer potassium monitoring intervals (e.g., every 3  months) might be indicated in concurrent users to prevent fatal cardiovascular events. (Source: Cardiovascu...
Source: Cardiovascular Drugs and Therapy - August 2, 2019 Category: Cardiology Source Type: research

Cost-Effectiveness of Strategies to Personalize the Selection of P2Y 12 Inhibitors in Patients with Acute Coronary Syndrome
ConclusionCost-effective strategies to personalize P2Y12 inhibition in ACS include clopidogrel +phenotype and genotype + liberal ticagrelor. Universal ticagrelor may be considered cost-effective at a higher WTP threshold ($150,000/QALY). Genotype + liberal ticagrelor exhibited the highest acceptability compared to clopidogrel + phenotype over the widest range of WTP thresholds and may be preferred. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - July 31, 2019 Category: Cardiology Source Type: research

Effect of a Therapeutic Strategy Guided by Lung Ultrasound on 6-Month Outcomes in Patients with Heart Failure: Randomized, Multicenter Trial (EPICC Study)
ConclusionsThe results of this study will provide more evidence about the impact of lung ultrasound on treatment monitoring in patients with chronic HF. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - July 22, 2019 Category: Cardiology Source Type: research

Safe and Efficacious Use of 1-Month Triple Therapy in Patients with Atrial Fibrillation and High Bleeding Risk Undergoing PCI
ConclusionsIn patients with AF undergoing PCI at lower ischemic risk and higher bleeding risk, 1 month of TT seems safe and efficacious. Further studies are warranted in patients at high ischemic risk. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - July 22, 2019 Category: Cardiology Source Type: research

The Role of Non-coding RNAs in Ischemic Myocardial Reperfusion Injury
AbstractMicroRNAs (miRNA) are non-coding RNAs that regulate gene expression in up to 90% of the human genome through interactions with messenger RNA (mRNA). The expression of miRNAs varies and changes in diseased and healthy states, including all stages of myocardial ischemia-reperfusion and subsequent ischemia-reperfusion injury (IRI). These changes in expression make miRNAs an attractive potential therapeutic target. Herein, we review the differences in miRNA expression prior to ischemia (including remote ischemic conditioning and ischemic pre-conditioning), the changes during ischemia-reperfusion, and the changes in miR...
Source: Cardiovascular Drugs and Therapy - July 22, 2019 Category: Cardiology Source Type: research

Long-Term Efficacy and Safety of Immunomodulatory Therapy for Atherosclerosis
AbstractBackground and AimsThe long-term effect of immune tolerance has not been explored so far in atherosclerosis. In the present study, we assessed the effect of mucosal tolerance to a multi antigenic construct expressing three peptides from ApoB, HSP60, and outer membrane protein from Chlamydia pneumonia (AHC) for 30  weeks at every 6-week interval to understand the kinetics of immune modulation in disease progression. The safety profile of the molecule was also evaluated in mice.MethodsApobtm2SgyLdlrtm1Her/J mice (5 –6 weeks) were orally dosed with multi antigenic construct (AHC) molecule on alternate ...
Source: Cardiovascular Drugs and Therapy - July 22, 2019 Category: Cardiology Source Type: research

Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients
ConclusionsIn addition to conventional oral glucose-lowering drugs, additional tofogliflozin administration had a favorable effect on left ventricular systolic and diastolic function in patients with T2DM. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - July 18, 2019 Category: Cardiology Source Type: research

Resolvin D1 Attenuates Myocardial Infarction in a Rodent Model with the Participation of the HMGB1 Pathway
ConclusionsOur results suggested that RvD1 pretreatment exhibited protective effects against MI through downregulation of HMGB1 and its related TLR4 and NF-κB expressions. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - July 6, 2019 Category: Cardiology Source Type: research

Effects of PDE-5 Inhibition on the Cardiopulmonary System After 2 or 4  Weeks of Chronic Hypoxia
AbstractPurposeIn pulmonary hypertension (PH), hypoxia represents both an outcome and a cause of exacerbation. We addressed the question whether hypoxia adaptation might affect the mechanisms underlying PH alleviation through phosphodiesterase-5 (PDE5) inhibition.MethodsEight-week-old male Sprague-Dawley rats were divided into two groups depending on treatment (placebo or sildenafil, a drug inhibiting PDE5) and were exposed to hypoxia (10% O2) for 0 (t0,n = 9/10), 2 (t2,n = 5/5) or 4 (t4,n = 5/5) weeks. The rats were treated (0.3 mL i.p.) with either saline or sildenafil (1.4 mg/Kg per day).ResultsTwo-week hypoxia changed ...
Source: Cardiovascular Drugs and Therapy - July 1, 2019 Category: Cardiology Source Type: research

Obesity-Related Genetic Determinants of Heart Failure Prognosis
ConclusionsSNPs rs10189761 and rs737337 were identified, for the first time, as independent predictors of major clinical outcomes in patients with HF. The data suggests an additive predictive value of these SNPs for a HF prognosis. In particular for obese patients, SNPs rs10423928, rs1800437, rs737337 and rs9351814 were related with a bad prognosis. Combined scores weighting the risk of each genomic variant could effect interesting new tools to stratify the prognostic risk of HF patients. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - June 17, 2019 Category: Cardiology Source Type: research

Oral Anticoagulation for Atrial Fibrillation Thromboembolism Prophylaxis in the Chronic Kidney Disease Population: the State of the Art in 2019
AbstractAtrial fibrillation (AF) is the most common cardiac rhythm disturbance and is associated with increased risk of thromboembolism. Oral anticoagulants are effective at reducing rates of thromboembolism in patients with AF in the general population. Patients with AF and concurrent chronic kidney disease (CKD) have higher risk of thromboembolism and bleeding compared with patients with normal renal function. Among moderate CKD and end-stage renal disease (ESRD) patients on chronic dialysis, the use of oral anticoagulants is controversial. Use of warfarin, while beneficial in non-CKD patients, raises a number of concern...
Source: Cardiovascular Drugs and Therapy - June 4, 2019 Category: Cardiology Source Type: research

Attainment of Guideline-Directed Medical Treatment in Stable Ischemic Heart Disease Patients With and Without Chronic Kidney Disease
AbstractBackgroundStable ischemic heart disease (SIHD) is prevalent in patients with chronic kidney disease (CKD); however, whether guideline-directed medical therapy (GDMT) is adequately implemented in patients with SIHD and CKD is unknown.HypothesisUse of GDMT and achievement of treatment targets would be higher in SIHD patients without CKD than in patients with CKD.MethodsThis was a retrospective study of 563 consecutive patients with SIHD (mean age 67.8  years, 84% Caucasians, 40% females). CKD was defined as an estimated glomerular filtration rate (eGFR) of
Source: Cardiovascular Drugs and Therapy - May 23, 2019 Category: Cardiology Source Type: research

After the AUGUSTUS Trial, Should Apixaban Be the Only Direct Oral Anticoagulant to Be Used in Triple Therapy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention?
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 10, 2019 Category: Cardiology Source Type: research

Efficacy of Antiplatelet Agent Usage for Primary and Secondary Prevention in Dialysis Patients: a Nationwide Data Survey and Propensity Analysis
ConclusionsAntiplatelet agent usage does not reduce CV events and total mortality in dialysis patients. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 8, 2019 Category: Cardiology Source Type: research

Pirfenidone in Heart Failure with Preserved Ejection Fraction —Rationale and Design of the PIROUETTE Trial
DiscussionPIROUETTE will determine whether pirfenidone is superior to placebo in relation to regression of myocardial fibrosis and improvement in myocardial energetics in patients with HFpEF and myocardial fibrosis (NCT02932566).Clinical Trial Registrationclinicaltrials.gov (NCT02932566)https://clinicaltrials.gov/ct2/show/NCT02932566 (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 8, 2019 Category: Cardiology Source Type: research

Plasma from Volunteers Breathing Helium Reduces Hypoxia-Induced Cell Damage in Human Endothelial Cells —Mechanisms of Remote Protection Against Hypoxia by Helium
ConclusionsPlasma of healthy volunteers breathing helium protects HUVEC against hypoxic cell damage, possibly involving circulating Cav-1. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 25, 2019 Category: Cardiology Source Type: research

Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation: a Systematic Review and Meta-analysis
ConclusionDOACs peri-cardioversion in patients with AF appears safe from both a bleeding and thromboembolic risk perspective. Available evidence supports the use of DOACs as standard of care peri-cardioversion in patients with AF. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 22, 2019 Category: Cardiology Source Type: research

BSCR Autumn Meeting Abstracts
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 16, 2019 Category: Cardiology Source Type: research

HFREF Patients and Atrial Fibrillation: Time to Reconsider the Appropriateness of the Atrial Fibrillation Ablation in This Patient Subset?
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 6, 2019 Category: Cardiology Source Type: research

“Real World” Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry
ConclusionsBetween 34 and 76% of symptomatic patients with HF-REF in a ‘real world’ population are eligible for treatment with sacubitril/valsartan, depending on background ACEI/ARB dose. The most common reason for ineligibility is a low natriuretic peptide level. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 23, 2019 Category: Cardiology Source Type: research

AST-120, an Adsorbent of Uremic Toxins, Improves the Pathophysiology of Heart Failure in Conscious Dogs
ConclusionsIS levels are increased in HF. AST-120 treatment reduces the levels of IS and improves the pathophysiology of HF in a canine model. AST-120 could be a novel candidate for the treatment of HF. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 23, 2019 Category: Cardiology Source Type: research

Special Issue: British Society for Cardiovascular Research
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 20, 2019 Category: Cardiology Source Type: research

Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients
This study aimed to analyze the direct medical costs for VTE management with rivaroxaban versus warfarin in Hong Kong Chinese patients.MethodsIn this retrospective observational study, VTE patients admitted to the Princess Margaret Hospital from March 2012 to February 2017 who were initiated and discharged with either rivaroxaban or warfarin were included. Patient demographic and clinical data, and healthcare resource utilization for VTE management were collected for the VTE index admission and 1-year post-discharge period.ResultsA total of 181 patients (90 in the rivaroxaban group; 91 in the warfarin group) were included....
Source: Cardiovascular Drugs and Therapy - March 19, 2019 Category: Cardiology Source Type: research

Activation of T Lymphocytes as a Novel Mechanism in Beta1-Adrenergic Receptor Autoantibody-Induced Cardiac Remodeling —Additional Information About TLR9 Involvement
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 18, 2019 Category: Cardiology Source Type: research

Medical Misinformation: Vet the Message!
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 12, 2019 Category: Cardiology Source Type: research

Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design
AbstractBackground and AimsDiabetes mellitus (DM) can cause left ventricular (LV) diastolic dysfunction, leading to heart failure with preserved ejection fraction (HFpEF). Dipeptidyl peptidase IV (DPP-IV) inhibitors have failed to reduce hospitalization due to HF in type 2 DM (T2D) patients in a large-scale clinical trial, despite their cardiovascular protective effects. Therefore, it is important to investigate whether DPP-IV inhibitors can improve LV diastolic dysfunction in T2D patients. The aim of the study was to evaluate whether teneligliptin, the strongest of the DPP-IV inhibitors, improves LV dysfunction or prevent...
Source: Cardiovascular Drugs and Therapy - March 9, 2019 Category: Cardiology Source Type: research

The Role of Thyroid Hormones in Heart Failure
AbstractCardiovascular diseases are the leading cause of death worldwide. Heart failure is the terminal manifestation of cardiovascular diseases, and its morbidity and mortality remain high. The prevalence of heart failure with preserved ejection fraction (HFpEF) among heart failure patients remains uncertain. However, recent studies have found that it ranged from 40 to 71%. There is still no effective treatment for HFpEF. Thyroid hormones (TH) have central regulatory actions in the cardiovascular system, particularly in the heart. Changes in plasmatic or tissue thyroid hormone levels are associated with significant altera...
Source: Cardiovascular Drugs and Therapy - March 7, 2019 Category: Cardiology Source Type: research

Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model
ConclusionsThese data suggest that vasodilator effects of macitentan and vardenafil combined may surpass monotherapy in vivo if drug doses are adjusted properly. Vasodilation by the longer-acting metabolite ACT-132577 was not further enhanced by vardenafil. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 2, 2019 Category: Cardiology Source Type: research

Examining the Risks of Major Bleeding Events in Older People Using Antithrombotics
ConclusionsUsing population-level data, we were able to obtain estimates on the bleeding risks associated with antithrombotic agents in older people often excluded from clinical trials because of either age or comorbidities. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 2, 2019 Category: Cardiology Source Type: research